Cargando…

Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study

INTRODUCTION: The objective of this study was to assess natural microbial agents, history and risk factors for total joint arthroplasty (TJA) infections in patients receiving tumor necrosis factor (TNF)α-blockers, through the French RATIO registry and a case-control study. METHODS: Cases were TJA in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilson, Mélanie, Gossec, Laure, Mariette, Xavier, Gherissi, Dalenda, Guyot, Marie-Hélène, Berthelot, Jean-Marie, Wendling, Daniel, Michelet, Christian, Dellamonica, Pierre, Tubach, Florence, Dougados, Maxime, Salmon, Dominique
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945039/ https://www.ncbi.nlm.nih.gov/pubmed/20637100 http://dx.doi.org/10.1186/ar3087

Ejemplares similares

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis
por: Gossec, Laure, et al.
Publicado: (2015)

Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)
por: Dougados, Maxime, et al.
Publicado: (2012)

Amelioration of cancer cachexia with preemptive administration of tumor necrosis factor-α blocker
por: Kang, Eun A, et al.
Publicado: (2022)

Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis
por: Castrejón, Isabel, et al.
Publicado: (2016)

Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
por: Leboime, Ariane, et al.
Publicado: (2009)

The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project
por: Leeb, Burkhard F., et al.
Publicado: (2009)

Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Spinal Cord Injury
por: Börcek, Alp Özgün, et al.
Publicado: (2015)

Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
por: Geri, Guillaume, et al.
Publicado: (2011)

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
por: Hamdi, Haïfa, et al.
Publicado: (2006)

Evaluation of the performances of ‘typical’ imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study
por: Molto, Anna, et al.
Publicado: (2019)

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
por: Bonafede, Machaon, et al.
Publicado: (2014)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study
por: Beydon, Maxime, et al.
Publicado: (2023)

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
por: Salliot, C, et al.
Publicado: (2009)

Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina
por: Fernandez-Bueno, I., et al.
Publicado: (2013)

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)
por: Dougados, Maxime, et al.
Publicado: (2023)

Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting
por: Blume, Steven W., et al.
Publicado: (2013)

Ineffectiveness of tumor necrosis factor-α blockers and ustekinumab in a case of type IV pityriasis rubra pilaris
por: Lernia, Vito Di, et al.
Publicado: (2015)

Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials
por: Gaujoux-Viala, C, et al.
Publicado: (2009)

Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain
por: Puyraimond-Zemmour, Déborah, et al.
Publicado: (2019)

Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA)
por: Dougados, Maxime, et al.
Publicado: (2015)

Multiple Autoimmune Skin Manifestations in a Patient with Crohn's Disease Treated with a Tumor Necrosis Factor-Alpha Blocker
por: Zattra, Edoardo, et al.
Publicado: (2015)

High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis
por: Elalouf, Ofir, et al.
Publicado: (2021)

Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review
por: Lavielle, Matthieu, et al.
Publicado: (2018)

Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts
por: Ez-Zaitouni, Zineb, et al.
Publicado: (2017)

Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years
por: Lucasson, Florian, et al.
Publicado: (2022)

Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers
por: Di Minno, Matteo Nicola Dario, et al.
Publicado: (2014)

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature
por: Park, Su-Kyung, et al.
Publicado: (2017)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Online Training on Skin Cancer Diagnosis in Rheumatologists: Results from a Nationwide Randomized Web-Based Survey
por: Viguier, Manuelle, et al.
Publicado: (2015)

COVID-19 in adults with dementia: clinical features and risk factors of mortality—a clinical cohort study on 125 patients
por: Vrillon, Agathe, et al.
Publicado: (2021)

Épidémie de COVID19 dans une unité de neuropsychogériatrie aiguë : aspects particuliers de la prise en charge chez des patients doublement vulnérables
por: Mhanna, Elsa, et al.
Publicado: (2021)

Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in Patients With Inflammatory Bowel Diseases
por: Marzano, Angelo V., et al.
Publicado: (2015)

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population
por: Schabert, Vernon F., et al.
Publicado: (2013)

Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients
por: Duarte, Catia, et al.
Publicado: (2021)

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients
por: Gossec, Laure, et al.
Publicado: (2019)

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
por: Van Kuijk, Arno W R, et al.
Publicado: (2023)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gu84l33ltn8dkgtj3jv7gs2eod